JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Management of Rheumatoid Arthritis

Mr. Akash Johri[1], Mr. Qumre Alam[2], Gaurav Kumar[3], Aman Khan[4], Manish Sharma[5]
1- Research Scholar, Apex University, Jaipur
2- Associate Professor, Innovative College of Pharmacy, Greater Noida
3,4,5-Research Scholar, Innovative College of Pharmacy, Greater Noida

ABSTRACT

The primary characteristic of rheumatoid arthritis, an inflammatory autoimmune illness, is synovitis. Extra articular organ involvement, interstitial pneumonia, and clinical symptoms such as pain, edema, stiffness in many joints, fever, and malaise are also present. Joint destruction follows in the early stages with rapid advancement. In addition to the appearance of persistent physical impairment, deformed joints are noted. Early sickness diagnosis and treatment are so essential. In palliative care, glucocorticoids and anti-inflammatory pharmaceuticals were employed; however, disease-modifying anti rheumatic drugs (DMARDs) are currently used to control the disease's progression and decrease immunological abnormalities**.**

DMARDs are classified into multiple groups, such as targeted synthetic DMARDs, conventional synthetic DMARDs, and biologic DMARDs. Now, when these drugs are used as prescribed, every patient's therapeutic objective might be remission. By maintaining remission, these drugs have also been shown to prevent joint deterioration and physical dysfunction over an extended period of time. Pathological mechanism-based treatment methods are currently being employed to treat a variety of autoimmune inflammatory illnesses, thanks to the advent of molecularly targeted medicines. Future medical advancements are expected to bring in precision medicine, therapeutic techniques aimed at medication holidays or cures, and safer and more effective treatments.

KEYWORDS: DMARD, biological, diagnosis, treatment, and rheumatoid arthritis.

1. INTRODUCTION

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that primarily affects the elderly and occurs more often in women than in men. There was geographical heterogeneity in the prevalence rate recorded in 2002, which varied from 0.5% to 1% of the population. RA mostly affects the synovial joint lining and can lead to financial hardships, premature death, and progressive disability. A symmetrical joint involvement may present with arthralgia, edema, redness, or even restricted range of motion. For the most desirable outcomes (i.e., less joint destruction, less radiologic progression, no functional disability, and DMARD-free remission), early diagnosis is thought to be the key improvement index. It is also thought to be cost-effective, as the first 12 weeks following the onset of early symptoms are thought to be the ideal therapeutic window. Early diagnosis is still difficult, though, since it mostly depends on clinical data from the patient's medical history, physical examination, and blood and imaging investigations. The causes of a delayed diagnosis range significantly throughout nations with different health care systems. Treatment and result for RA are significantly influenced by patient awareness of RA, patient desire to seek medical guidance, the amount of time from the onset of symptoms to receiving suitable treatment, and the physician's diagnostic skill. Extra-articular signs include keratitis, pulmonary granulomas (rheumatoid nodules), pericarditis/pleuritis, small artery vasculitis, and other non-specific extra-articular symptoms are possible in cases of poorly controlled or severe disease.

The goal of the treatment plan is to quickly reach a low disease activity state (LDAS) and facilitate an early diagnosis, even though there is presently no known cure for RA. Numerous composite scales are available for evaluating disease activity, including the Clinical Disease Assessment Index (CDAI), Simplified Disease Activity Assessment Index (SDAI), and Disease Activity Score employing 28 joints (DAS-28). Rheumatologists must periodically and properly assess disease activity in order to modify the treatment plan and achieve complete suppression of the illness's activity (clinical remission). Non-steroidal anti-inflammatory medications (NSAIDs) and corticosteroids, when used universally in pharmacologic therapy, have been shown to be useful in reducing pain and stiffness but not in slowing the course of the disease. The ability of DMARDs to effectively reduce disease activity and significantly lessen and/or postpone joint deformity has drawn a lot of attention throughout the past 20 years. Biological DMARDs, innovative prospective small molecules, and conventional synthetic medicines are all included in the therapeutic classification. Past DMARDs include minocycline, auranofin, and cyclosporine and azathioprine are rarely used as contemporary treatments. Recently, a number of biological DMARDs have surfaced such as TNF-inhibitor (Imradl, Amjevita, Renflexis, Erelzi, Cyltezo) anti-IL-6 receptor antibody, anti-CD20 antibody

(Truxima, Rixathon)(Kevzara), JAK inhibitor (Olumiant), and RANKL antibody (Pralia).

2. PATHOGENESIS OF RA:

Based on the existence or lack of anti-citrullinated protein antibodies (ACPAs), there are two main subgroups of RA. The calcium-dependent enzyme peptidylarginine-deiminase (PAD) catalyzes the process of citrullination, which is the transformation of a positively charged arginine into a polar but neutral citrulline as a result of a post-translational at ratio of RA, ACPAs are found in about 67% of cases can provide as a helpful diagnostic resource for patients with early-stage, non- differentiated arthritis and offer a sign of most likely the progression of the illness to RA. The positive ACPA. A more aggressive clinical pattern is present in a subset of RA compared to the RA. ACPA-negative subset According to reports, ACPA-negative genetic connection patterns and differential expression are distinct in RA immunological cells' reactions to citrullinated antigens from those of the subset ACPA-positive regarding therapy. Future research on possible pathophysiological differences between these two categories may be necessary, as suggested by this. In order to complete this evaluation, we will concentrate on the RA development into the ACPA-positive subtype of RA divide the procedure into multiple unique phases. It is important to understand that but that these phases could happen one after the other or concurrently.

3. TRIGGERING STAGE:

Because of ACPA's excellent specificity (>97%) in clinical practice, it is currently frequently utilized to diagnose and predict RA. The pathogenesis of ACPA involves an atypical antibody reaction to many citrullinated proteins found throughout the body, such as histones, fibrin, vimentin, fibronectin, α-enolase, type II collagen, EBNA-1, and fibrin. There is evidence linking genetic and environmental variables to the generation of ACPA. Known as "shared epitopes" (SEs), genes producing HLADR, particularly HLA-DR1 and HLA-DR4, are the biggest genetic risk factor linked to ACPA-positive RA. It is believed that SE affects the result of RA via the generation of ACPA and is therefore a major risk factor for the manufacture of ACPA. Tyrosine

phosphatase non receptor protein. Protein tyrosine phosphatase non receptor type 22 (PTPN22), a lymphoid-specific protein tyrosine phosphatase, has also received a lot of interest due to polymorphisms linked to ACPA-positive RA and its role in the condition across a range of ethnic groups. Consequently, it might function as a strong inhibitor of T cell activation, which would impact the synthesis of ACPA. It has been discovered that the synthesis of ACPA in RA is connected to genetic variations in α1-antitrypsin. More

research is necessary to determine if the production is caused by altered autophagy caused by the mutant α1-antitrypsin Z or is directly related to α1-antitrypsin deficit per se. ACPA synthesis is correlated with an enhanced response of the type I interferon gene linked to Th2 cell induction and B cell proliferation. Recently, the gene expression profiles of patients with ACPA-positive and ACPA-negative RA were compared by certain studies. The connection between the identified genes and ACPA synthesis is a crucial piece of the puzzle. Additionally, people who have a family history of RA are more susceptible to developing RA. First-degree relatives of RA patients had a threefold increased chance of acquiring RA, despite the fact that family variables affect RA in both men and women equally.

In RA, the environment serves as a trigger for the creation of ACPA, and genes and the environment are combined through epigenetic control. In RA, the reactivity of autoantibodies to citrullinated antigens is influenced by gene-environment interaction. ACPAs can be identified well in advance of joint symptoms manifesting. This event raises the possibility that the joints are not the site of autoimmune onset. In addition to antigen-presenting cells (APCs) like B cells and conventional dendritic cells (DCs), lung exposure to noxious chemicals such as smoke, silica dust, nanosized silica, or carbon-derived nanomaterials can activate mucosal toll-like receptors (TLRs), which in turn activate Ca2+-mediated PADs. Mutations in the coatomer subunit α gene may impair the transport of endoplasmic reticulum (ER) to the Golgi apparatus, leading to autoimmune-mediated lung disorders and arthritis in hereditary cases. This suggests a link between lung and joint diseases. Furthermore, smoking in relation to the HLA-DR SE gene may cause immune responses specific to citrullinated proteins that are unique to RA. In RA that is ANPPA-positive, smoking and genotype interaction are mediated by DNA methylation. Three infectious agents— Epstein-Barr virus (EBV), Aggregatibacter actinomycetemcomitans (Aa), and Porphyromonas gingivalis—are thought to be autoimmune triggers in RA, and there is a wealth of evidence supporting this theory. Another potential trigger location is the periodontal space. In a clinical environment, RA patients had evidence of prior Aa infection in 47% of cases, compared to 11% in the control group. P. gingivalis infection causes the production of citrullinated auto antigens and ACPA in two ways that have been documented: first, through the action of P. gingivalis's arginine ginpains (Rgps) and PAD, which can cleave proteins at arginine residues and citrullinate proteins to produce more neoantigens; second, through the induction of neutrophil extracellullar traps(NETs) during the process of NETosis by P. gingivalis. Citrullinated autoantigens are generated by NETosis, which is induced by ACPAs. EBV can impact B cells that produce ACPA, and RA can show signs of compromised EBV control because the overabundance of specific uncommon bacterial lineages in RA patients might lead to dysbiosis, the digestive tract is another mucosal organ implicated in the etiology of RA. A healthy diet may

also help lower the chance that RA that is ACPA-positive will develop in those who are 55 years of age or younger. Furthermore, the pathophysiology of RA has been linked to hormone levels, albeit a clear correlation with ACPAhas not been demonstrated. It has been suggested that changes in the control of gene expression caused by long non-coding RNAs and microRNAs may play a role in the pathogenesis of RA. It is yet unknown how other epigenetic alterations, such as sumoylation, histone methylation, acetylation, and deacetylation, contribute to RA and what function they serve in the disease. It would be difficult yet worthwhile to translate the aforementioned observations into practical treatments and investigate their interactions with the genome. It is difficult to translate the aforementioned observations into practical treatments and investigate how they interact with the genome, but it would be significant. It is important to make clear the specific knowledge. Understanding every risk factor that can result in the onset of RA so that instruments can be created to offer early diagnostic and susceptibility ratings, as furthermore to find novel molecular targets for customized medication.

4. MATURATION STAGE:

This phase begins at the location of bone marrow or secondary lymphoid tissues. The term "epitope spreading" describes how the release of self-antigens causes the immune system to develop in response to endogenous epitopes. The immune system's reaction to autoantigens may be present outside of the joints for many years before the disease manifests. Before joint symptoms appear in this stage, epitope dissemination and a steadily rising ACPA titer can persist for several years. Initial ACP levels seem to be crucial in determining how long it will take for an illness to manifest. The breakdown of immunological tolerance is reflected in the generation of ACPA. Numerous citrullination neoantigens would therefore stimulate T cells that are dependent on MHC class II,

which would then assist B cells in producing more ACPA. ACPA can cause discomfort, bone. N-acetylglucosamine-6-sulfatase (GNS) and filamin A (FLNA), two RA-specific autoantigens, have been shown in one study to connect microbial immunity with autoimmune reactions in the joint. Furthermore, it has been suggested that citrullination has a special function during osteoclast differentiation and ACPA-induced osteoclast activation, which may help to explain key aspects of the disease's slow progression, such as why the joints are affected. The targeted autoantigen's biologic characteristics, as well as regional microvascular, neurologic, and biomechanical elements and potential microtrauma-related mechanisms, are additional probable contributing factors.

5. TARGETING STAGE:

RA-related joint involvement typically manifests characteristically as synovitis in symmetrical small joints. The synovial membrane's outward reflection is joint swelling inflammation that happens after an immunological response. As shown in figure below.



Fig 1. The interplay of genes and environmental variables can cause RA in the probable triggersites (gut, lung, and so on). This is defined by the initiation of self-protein citrullination, which leads to the formation of autoantibodies against citrullinated peptides. The self-protein citrullination and maturation of ACPA may be induced by lung exposure to noxious chemicals, infectious agents (such as Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Epstein-Barr virus), gut microbiota, and dietary factors. A post-translational alteration known as citrullination is mediated by the calcium-dependent enzyme PAD, which converts positively charged arginine into polar but neutral citrulline. Both macrophages and granulocytesin RA have the ability to release PAD. An aberrant antibody response to several citrullinated proteins, such as histones, fibrin, vimentin, fibronectin, Epstein-Barr Nuclear Antigen 1, α- enolase, type II collagen, and fibrin, which are found all over the body, causes ACPA. Numerous citrullination neoantigens would stimulate T cells dependent on MHC class II, which would then assist B cells in producing more ACPA. Loss of tolerance is another term for the stage. ACPA antibodies against citrullinated proteins, peptidyl-argininedeiminase in PAD, rheumatoid factor (RF), and RA (rheumatoid arthritis).

Chronic synovitis, or the inability to resolve inflammation, is the outcome of ACPApositive RA, which is largely caused by interactions between the two immune systems. It has been discovered that monocytes and macrophages extensively infiltrate synovial membranes and play a key role in the pathophysiology of inflammation. When ACPA binds to citrullinated Grp78 expressed on the surface of monocytes or macrophages, it can increase TNF-α production and NF-kB activity. The surface α-enolase of monocytes and macrophages stimulates the synthesis of pro-inflammatory mediators. In the setting of inflammatory RA, it is also necessary to take into account the imbalances between proinflammatory M1 macrophage and anti-inflammatory M2 macrophage. In fact, a recent study found that osteoclastogenesis in RA patients is influenced by an imbalance in M1/M2 monocytes. notably in RA that is ACPA-positive. Furthermore, one study found that the pro-inflammatory cytokine interleukin (IL)-17A in RA joint samples

is mainly confined to mast cells, and that TLR ligand and ACPA can activate mast cells. There have also been reports of DC buildup in the articular cavity. Myeloid DCs in particular have been demonstrated to stimulate T cell differentiation as an APC. A thorough comprehension of myeloid DC activity in RA may lead to improved RA therapeutic approaches. Additional potential innate immune pathways include stimulation of natural killer cells and neutrophil NETosis. However, a number of scientists believe that the adaptive immune system plays a significant role in RA illness pathophysiology.

6. FULMINANT STAGE:

6.1. Hyperplastic synovium

Synovium that is hyperplastic specialized FLSs and macrophages generated from bone marrow coexist in the synovium.60 In addition to digesting waste products, synovial cells secrete hyaluronic acid and lubricin for joint lubrication and function, which helps to maintain the stable state of the joint. In RA, hyperplastic synovium is caused by FLS dysfunction. The lack of contact inhibition, which is a key factor in RA, leads to the aberrant proliferation of FLS and produces inflammatory cytokines and proteinases such tissue inhibitors of metalloproteinases (TIMPs) and matrix metalloproteinases (MMPs) that prolong joint degradation. They produce a milieu that promotes neutrophil accumulation, T cell and B cell survival.

6.2. Cartilage damage

Cartilage, which is made up of chondrocytes and a dense, well-organized extracellular matrix (ECM) that these chondrocytes create and comprises type II collagen and glycosaminoglycans

(GAGs), is an essential component of synovial joints. In RA, the hyperplastic synovium directs adhesion and invasion, seriously damaging the cartilage. On the other hand, FLS activity may be further stimulated by inflammatory signals, including those that are released by the ECM. MMPs, a disintegrin-like metalloprotease with thrombospondin type 1 motifs 4 and 5, and cathepsins are the mediators of cartilage destruction. MMPs are produced by FLS and have the ability to encourage the type II collagen network's disintegration, which can lead to biomechanical dysfunction. It is thought that the main proteinase responsible for breaking down the collagenous cartilage matrix is membrane-type I MMP.

6.3. Bone erosion

One of the pathological characteristics of RA is bone loss, which can be systemic, periarticular, or localized. The activation of osteoclasts and the inhibition of osteoblasts lead to bone loss. It is most certainly the case that "periarticular" bone loss refers to cellular modifications of the subchondral bone marrow, including osteoclast differentiation and the development of inflammatory infiltrates. Whether inflammation or autoimmunity is the primary cause of bone loss is still up for debate. The following data supports the traditional inflammatory theory: TNF-α,

IL-6, IL-1β, IL-17, and other pro-osteoclastogenic inflammatory cytokines associated with RA may, in the right conditions, inhibit bone formation by acting as suitable signals such as macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL).

There are two potential pathways for bone loss in RA. The first involves autoimmune processes that initiate structural bone damage. The initial process concerns the development of the immune complex and the differentiation of osteoclasts mediated by Fc receptors. Osteoclasts are the perfect antigenic target for anti-citrullinated protein antibodies (ACPA) because the second is the development of anti-citrullinated vimentin antibodies against the most citrullinated protein. It has been found that osteoclastogenesis, bone resorption, and bone loss are caused by ACPA binding to osteoclast precursors. A hole is essentially created by bone resorption and is typically located where the synovial membrane penetrates into the periosteum. This area is referred to as a naked area based on specific anatomical characteristics. The subchondral bone is essential for preserving the homeostasis of joints that support weight.

6.4. Systemic consequences

Patients with RA have been shown in numerous studies to have an increased risk of cardiovascular events. The risk factors could be associated with cytokines that enhance endothelial activation and may cause atheromatous plaques to become unstable.

Low-density, high-density, and total cholesterol are all lower in patients with active, untreated RA. Moreover, RA affects the lungs by causing fibrotic and inflammatory diseases, the exocrine glands by causing secondary Sjogren's syndrome, the skeletal muscles by causing sarcopenia, the bones by causing osteoporosis, and the brain by causing fatigue and decreased cognitive function. Lastly, cancer, particularly hematologic and renal malignancies, may be more common in RA patients.

7. MODERN RA PHARMACOLOGIC THERAPIES

The two main pillars of modern RA treatment are disease modification and symptomatic management. Patients receiving delayed DMARD medication were found to have an increased risk of radiographic joint space narrowing and bone erosions, according to a meta-analysis of 12 published studies.77 Bony erosions show up on radiographs in individuals with poorly managed RA within two years of the condition's beginning, and these erosive alterations are associated with worse functional outcomes.78 It is therefore necessary to make an immediate referral to a rheumatologist for a patient with otherwise unexplained new onset polyarthritis in order to establish the diagnosis of RA and to start a DMARDs-based treatment strategy that aims to prevent deformity while achieving disease remission. Strong and efficient anti-inflammatory medications, oral corticosteroids may help change a disease's course.

This must be balanced against its well-known negative effects, though. Symptomatic management, which entails common sense approaches to address the key signs and symptoms of joint stiffness, like pain and fatigue, is crucial throughout the course of the illness. Exercise is crucial for maintaining joint flexibility and function, and since smoking affects the production of antibodies, quitting is a universal recommendation for all RA patients.

7.1. Conventional Synthetic DMARDs (cs DMARDs) Methotrexate (MTX)

A vital part of treating rheumatoid arthritis (RA) is MTX, a modified folate variant with increased binding affinity for dihydrofolate reductase (DHFR), either by itself or in conjunction with other disease-modifying antirheumatic medications (DMARDs). In short-term RA treatment, recent meta-analyses confirm its significant clinical advantage over a placebo; nonetheless, a 16% dropout rate due to adverse effects is reported. To enhance its therapeutic benefits, MTX participates in adenosine signaling, folate antagonism, and pathway regulation. Single nucleotide polymorphisms (SNPs) linked to MTX responsiveness have been found through genetic investigations; however, inconsistent findings require additional genomicinvestigation.

Weekly administration of modest dosages of MTX necessitates routine monitoring to determine the optimal dosage and evaluate any immunosuppressive effects. Supplementation can reduce side effects, such as accelerated nodulosis brought on by MTX.

Leflunomide

Leflunomide provides an alternate method of lowering inflammation in RA joints by blocking dihydroorotate enzymes, which are essential for the production of DNA and RNA. When leflunomide is taken 10 mg per day for the first three days and then 20 mg per day, it works similarly to MTX in terms of clinical, functional, and structural efficacy. Dosage decrease may be necessary due to side effects such as headache, nausea, and diarrhea. Careful thought must be given to well-documented medication interactions and possible risks to nursing infants and fetuses. It is essential to regularly check liver function, allergic responses, and gastrointestinal problems.

Sulfasalazine (SSZ)

Due to its anti-inflammatory and antibacterial qualities, SSZ is useful in lowering joint counts and delaying the advancement of radiography in patients with RA. The therapeutic benefits of 5- aminosalicylic acid and sulfapyridine are attributed to their metabolites. SSZ inhibits the creationof osteoclasts, suppresses the expression of TNF-α, affects the generation of adenosine, and lowers the secretions of inflammatory cytokines. Leukopenia, rash, and gastrointestinal toxicity

are typical side effects. Frequent monitoring of laboratory tests reduces the likelihood of side effects, and during pregnancy and lactation, care should be used while weighing the risks and benefits.

Hydroxychloroquine

In RA, hydroxychloroquine reduces joint inflammation and the production of pro-inflammatory cytokines by interfering with the interaction between T helper cells and antigen-presenting macrophages. Its slow start of action over a period of two to six months demonstrates both radiographic damage retardation and long-term functional improvement. High dosages and continuous use are linked to adverse effects, which are mostly gastrointestinal, dermatological, and ophthalmologic. Even after withdrawal, risk factors for retinal toxicity need to be effectively screened for early diagnosis.

7.2. Biological DMARDs (bDMARDs)

bDMARDs are a broad class of medications that target particular molecules or processes involved in the inflammation of RA. The first bDMARDs were TNF-α inhibitors; these were followed by drugs that targeted the B lymphocyte antibodies CD-20, IL6, and CD28. Important inflammatory mediator TNF-α activates responses via receptors 1 and 2, impacting several pathways including RANKL signaling and NF-κB. TNFi, particularly etanercept, infliximab, and adalimumab, has emerged as the treatment of choice for RA patients who are not responding to traditional therapies. Biosimilars offer substitute solutions.

B-Cell Depletion and Inhibition Antibodies

Rituximab works effectively in RA by reducing B cells, namely CD20-positive B lymphocytes. In clinical trials, the anti-B lymphocyte stimulator antibody belimumab was less successful. Treatment for RA can also be achieved with T-cell modulator abatacept, which affects T-cell co- stimulation. While the results of targeting T cells with different drugs have been inconsistent, continuing trials are looking into promising possibilities.

IL-6 Inhibition

An IL-6 receptor inhibitor called tocilizumab reduces neutrophil levels without posing a serious risk of infection, making it a promising treatment for RA. There are potential substitutes in clinical studies, such as sirukumab and other IL-6 inhibitors.As shown in figure below.

IL-1 inhibition

One cytokine that can have both proinflammatory and immunological effects is IL-1. IL-1RI and IL-1RII are two distinct immunoglobulin-like membrane-bound IL-1 receptors. Unlike IL-1RI, IL-RII functions as a decoy receptor at the cell surface, binding to and inhibiting IL-1 rather than transmitting signals. Both IL-1 receptors have the ability to bind to IL-1 in serum, controlling the cytokine's bioavailability. An injectable that is administered once a day, anakinra (rHuIL-1ra) is a non-glycosylated recombinant version of the IL-1 receptor antagonist. Its extra N-terminal methionine sets it different from the normal human protein. It binds to the IL-1 receptor and reduces the activities of IL-1α and IL-1β.



Fig 2. Cells and key receptors/pathways targeted by current therapy strategies. RANKLreceptor activator of nuclear factor-KB ligand, JAK Janus kinase/signal transducers.

Osteoclast Differentiation Factor

Limiting bone erosions in RA may be aided by denosumab, which inhibits bone resorption by targeting RANKL. Early data points to denosumab's potential use in conjunction with DMARDs.

Small-Molecule DMARDs

Jakinibs are a novel class of oral RA medications that target JAK-STAT pathways. The firstJakinib to be approved, tofacitinib, shows promise despite the risk of infection. Opportunities for customized treatment are presented by the development of baricitinib and other Jakinibs with different levels of selectivity.

Future Perspectives

Understanding the pathogenesis of RA better opens up possibilities for precision medicine, including gene therapy. In animal models, notch1 and TNF-α gene silencing exhibit potential. Potential treatment possibilities are highlighted by early-stage developments in targeting specific cells, such as B cells and T cells. Promising research is being done on novel targets such asneural pathways, Bruton's tyrosine kinase, and TLRs. The field of RA treatment is constantly changing, and new methods like TGF-β regulation, DC modification, and stem cell therapy are being studied.

In the future, several medications may target T cells and B cells to induce seroconversion or postpone the onset of joint degradation. More research is being done on APC function reduction and antibody pro-inflammatory property modulation.Innovative strategies that could be important therapeutic targets include TLRs, Bruton's tyrosine kinase, the phosphoinositide-3- kinase pathway, TGF-β, neural pathways, and DCs. These strategies are also of great interest. A potential treatment target for RA, bruton's tyrosine kinase is implicated in a number of signaling pathways that follow the pre-B-cell receptor and FcR.The security and There have been reports on the tolerability of expanded adipose-derived stem cell intravenous infusions in patients with refractory RA.

8. CONCLUSION

One frequent autoimmune arthritis that develops when the body's immune system overreacts and starts attacking healthy tissues is rheumatoid arthritis. Significant inflammation is caused by these attacks in the body's tissues, including the joints and organs. Joint pain, stiffness, and edema are typical signs of RA, as are systemic symptoms including low-grade fever and exhaustion. Although it can also affect larger joints, RA typically begins in the tiny joints of the hands and feet. Although the specific origin of RA is unknown, researchers have long suspected that environmental and genetic factors may play a role. In addition, exposure to chemicals and pollutants, long-term stress, psychological or physical trauma, lifestyle choices, disease, or bacterial or viral infection are thought to be triggers for the development of RA. Though it can be controlled and treated, RA is presently incurable. In addition to preventing joint injury and impairment, early diagnosis and appropriate therapy can lessen pain and other disease symptoms.

The inflammatory response in persons with RA is hyperactive. Inflammation caused by RA can cause serious joint damage, disability, and consequences from the disease if left untreated. Although RA has no known treatment, it is a curable and controllable condition. Only studies with small sample sizes, cross sectional designs, and/or clinical settings which might not be entirely typical of the Indian population are included in this review. More comprehensive research is required because the present observational studies are insufficient to draw conclusions about the overall Indian RA population.

9. REFERENCES

1. Silman, A. J. & Pearson, J. E. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4(Suppl. 3), S265–S272 (2002).
2. van der Linden, M. P. et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 62, 3537–3546 (2010).
3. Moura, C. S. et al. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res. Ther. 17, 197 (2015).
4. Cho, S. K. et al. Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. Korean J. Intern. Med. 113, (2017).
5. Raza, K. et al. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann. Rheum. Dis. 70, 1822–1825 (2011).
6. Ometto, F. et al. Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmun. Rev. 9, 161–164 (2010).
7. Grennan, D. M., Gray, J., Loudon, J. & Fear, S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann. Rheum. Dis. 60, 214–217 (2001).
8. Nishimura, K. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 146, 797–808 (2007).
9. Bizzaro, N. et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res. Ther. 15, R16 (2013).
10. Malmstrom, V., Catrina, A. I. & Klareskog, L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat. Rev. Immunol. 17, 60–75 (2017).
11. Padyukov, L. et al. A genome-wide association study suggests contrasting associations in ACPA- positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259–265 (2011).
12. Schuerwegh, A. J. et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 107, 2586–2591 (2010).
13. van Dongen, H. et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56, 1424–1432 (2007).

14. Sellam, J. et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 63, 933–938 (2011).

15. Seegobin, S. D. et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res. Ther. 16, R13 (2014).

16. Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).

17. Okada, Y. et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum. Mol. Genet. 23, 6916–6926 (2014).

18. Mori, M., Yamada, R., Kobayashi, K., Kawaida, R. & Yamamoto, K. Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J. Hum. Genet. 50, 264–266 (2005).

19. Nabi, G. et al. Meta-analysis reveals PTPN22 1858C/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population. Autoimmunity 49, 197–210 (2016).

20. Goh, L. L. et al. NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese. Rheumatol. Int. 37, 1295–1302 (2017).

21. McCarthy, C. et al. Brief report: genetic variation of the alpha1 -antitrypsin gene is associated with increased autoantibody production in rheumatoid arthritis. Arthritis Rheumatol. 69, 1576– 1579 (2017).

22. Castaneda-Delgado, J. E. et al. Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production. Front. Immunol. 8, 285 (2017).

23. Ding, B. et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum. 60, 30–38 (2009).

24. Schiff, M. H. et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging 23, 167–178 (2006).

25. Kuo, C. F. et al. Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families: a nationwide population-based study. Rheumatology 56, 928–933 (2017).

26. Hensvold, A. H. et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann. Rheum. Dis. 74, 375–380 (2015).

27. van der Woude, D. et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat. Genet. 42, 814–816 (2010). author reply 6.

28. Stolt, P. et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann. Rheum. Dis. 69, 1072–1076 (2010).

29. Mohamed, B. M. et al. Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine 7, 1181–1195 (2012).

30. Too, C. L. et al. Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study. Ann. Rheum. Dis. 75, 997–1002 (2016).

31. Watkin, L. B. et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat. Genet. 47, 654–660 (2015).

32. Klareskog, L. et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54, 38–46 (2006).